Dapsone Gel
FDA Recall NDC 72578-094

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 4 recorded enforcement report(s) associated with Dapsone (NDC 72578-094). A significant event, classified as Class II, was initiated on Dec 10, 2024 by Viona Pharmaceuticals Inc. The reported reason for this action was: "Crystallization"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

December 2024 Class II Recall: Crystallization

Recall Number
Class II Ongoing
Reason for Recall
Crystallization
Initiated
Dec 10, 2024
Reported
Jan 08, 2025
Quantity
23304 packs

Recall Profile & Regulatory Data

Event ID
95930
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
VIONA PHARMACEUTICALS INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide
Product Description
Dapsone Gel 7.5%, 60 g, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahemedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-02. packaged in an Airless pump pack
Batch or Lot Expiration Information
Lot# Lots T400513, Exp Date 02/2026; T400807, Exp Date 03/2026; T401152, Exp Date 06/2026; T401303, Exp Date 07/2026; T401304, Exp Date 07/2026; T401399, Exp Date 07/2026 & T401696 Exp Date 08/2026.
Affected Packages Involved in this Recall
72578-094-01Product
72578-094-02Product
72578-094-03Product

December 2024 Class II Recall: Crystallization

Recall Number
Class II Ongoing
Reason for Recall
Crystallization
Initiated
Dec 10, 2024
Reported
Jan 08, 2025
Quantity
2760 packs

Recall Profile & Regulatory Data

Event ID
95930
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
VIONA PHARMACEUTICALS INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide
Product Description
Dapsone Gel 7.5%, 90 g, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-03. packaged in an Airless pump pack
Batch or Lot Expiration Information
Lot# Lots T400514, Exp Date 02/2026 & T400808, Exp Date 03/2026
Affected Packages Involved in this Recall
72578-094-01Product
72578-094-02Product
72578-094-03Product

October 2024 Class II Recall: Crystallization

Recall Number
Class II Ongoing
Reason for Recall
Crystallization
Initiated
Oct 29, 2024
Reported
Nov 13, 2024
Quantity
6048 pumps

Recall Profile & Regulatory Data

Event ID
95650
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
VIONA PHARMACEUTICALS INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
USA Nationwide
Product Description
Dapsone Gel 7.5%, 60 gram pump, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-02.
Batch or Lot Expiration Information
Lot# Lots T401151, Exp, 06/30/2026; T400806, Exp 03/31/2026
Affected Packages Involved in this Recall
72578-094-01Product
72578-094-02Product
72578-094-03Product

September 2024 Class II Recall: Crystallization

Recall Number
Class II Ongoing
Reason for Recall
Crystallization
Initiated
Sep 24, 2024
Reported
Oct 23, 2024
Quantity
2544 pumps

Recall Profile & Regulatory Data

Event ID
95412
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
VIONA PHARMACEUTICALS INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
NY
Product Description
Dapsone Gel 7.5%, 60 gram pump, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-02.
Batch or Lot Expiration Information
Lot# : T400512, Exp 02/28/2026
Affected Packages Involved in this Recall
72578-094-01Product
72578-094-02Product
72578-094-03Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.